search
Back to results

Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes (T1D)

Primary Purpose

Type1 Diabetes Mellitus, Adiposity

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Euglycemic hyperinsulinemic clamp with tracer enhancement
Euglycemic hyperinsulinemic clamp with tracer enhancement
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Type1 Diabetes Mellitus

Eligibility Criteria

12 Years - 24 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • All Participants:

    1. Clinical diagnosis of T1D
    2. HbA1c ≤9%
    3. Diabetes duration of at least 12 months

Adolescents with T1D:

  1. Age 12-16 years
  2. BMI <75th for lean pediatric subjects, > 85th percentile for overweight/obese pediatric subjects;
  3. Tanner stage 2-5
  4. Parent able to provide written consent and participant able to provide assent
  5. Not meeting MRI safety criteria
  6. Claustrophobia that will prevent participation in the MRI

Lean, young adults with T1D:

  1. Age 18-24 years
  2. BMI 18.5-24.9 kg/m2
  3. Able to provide written consent.

Exclusion Criteria:

  1. Use of adjunctive diabetes medications
  2. Weight loss medications within the past six months
  3. Current psychiatric disorders, including eating disorders (DSM-V criteria)
  4. Known liver disease other than nonalcoholic hepatic steatosis
  5. Females who are pregnant or lactating
  6. Anemia or another medical condition that precludes participation in the study

Sites / Locations

  • Yale Pediatric Diabetes Research Program

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

Adolescent Overweight

Adolescent Typical

Young Adult

Arm Description

The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.

The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.

The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement

Outcomes

Primary Outcome Measures

Rate of Glucose Metabolism
euglycemic hyperinsulinemic clamp
Rate of Lipid Metabolism
euglycemic hyperinsulinemic clamp
Hepatic Sensitivity to Low Dose Insulin
euglycemic hyperinsulinemic clamp
Peripheral Sensitivity to High Dose Insulin
euglycemic hyperinsulinemic clamp

Secondary Outcome Measures

Full Information

First Posted
June 15, 2018
Last Updated
April 6, 2023
Sponsor
Yale University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT03582956
Brief Title
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
Acronym
T1D
Official Title
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Terminated
Why Stopped
Covid
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
August 12, 2022 (Actual)
Study Completion Date
August 12, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the effects of adiposity on resistance to insulin's ability to suppress hepatic glucose production and to stimulate peripheral glucose metabolism in adolescents with type 1 diabetes. In addition, this study will also examine the role of fatty liver disease on the insulin resistance of obesity in adolescents with type 1 diabetes.
Detailed Description
A major focus of this program of research will be directed at advancing the understanding of the metabolic consequences of obesity and puberty in adolescents with T1D. Thus, an innovative aspect of this research is that it will be the first to use these sophisticated metabolic techniques to examine the effects of obesity and hepatic steatosis on insulin sensitivity in pubertal adolescents with T1D; namely, the 2-step hyperinsulinemic euglycemic clamp with tracer enhancement, which will allow for definition of hepatic and peripheral insulin resistance, glycerol turnover, and glucose and fat oxidation. Further, a second novel aspect is that this will be the first study to utilize gold standard MRI methods to quantify and compare intrahepatic fat content in lean and obese adolescents with T1D. This will allow a global and more detailed understanding of the potential alterations of insulin's effects on key insulin sensitive tissues in youth that are impacted by both T1D and obesity. Furthermore, evaluation of biomarkers for insulin resistance and fatty liver disease in this population will be performed for the first time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type1 Diabetes Mellitus, Adiposity

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Adolescent Overweight
Arm Type
Other
Arm Description
The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
Arm Title
Adolescent Typical
Arm Type
Other
Arm Description
The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
Arm Title
Young Adult
Arm Type
Other
Arm Description
The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement
Intervention Type
Procedure
Intervention Name(s)
Euglycemic hyperinsulinemic clamp with tracer enhancement
Intervention Description
To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
Intervention Type
Procedure
Intervention Name(s)
Euglycemic hyperinsulinemic clamp with tracer enhancement
Intervention Description
A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
Primary Outcome Measure Information:
Title
Rate of Glucose Metabolism
Description
euglycemic hyperinsulinemic clamp
Time Frame
120 minutes
Title
Rate of Lipid Metabolism
Description
euglycemic hyperinsulinemic clamp
Time Frame
120 minutes
Title
Hepatic Sensitivity to Low Dose Insulin
Description
euglycemic hyperinsulinemic clamp
Time Frame
120 minutes
Title
Peripheral Sensitivity to High Dose Insulin
Description
euglycemic hyperinsulinemic clamp
Time Frame
120 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
24 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All Participants: Clinical diagnosis of T1D HbA1c ≤9% Diabetes duration of at least 12 months Adolescents with T1D: Age 12-16 years BMI <75th for lean pediatric subjects, > 85th percentile for overweight/obese pediatric subjects; Tanner stage 2-5 Parent able to provide written consent and participant able to provide assent Not meeting MRI safety criteria Claustrophobia that will prevent participation in the MRI Lean, young adults with T1D: Age 18-24 years BMI 18.5-24.9 kg/m2 Able to provide written consent. Exclusion Criteria: Use of adjunctive diabetes medications Weight loss medications within the past six months Current psychiatric disorders, including eating disorders (DSM-V criteria) Known liver disease other than nonalcoholic hepatic steatosis Females who are pregnant or lactating Anemia or another medical condition that precludes participation in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle Van Name, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale Pediatric Diabetes Research Program
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes

We'll reach out to this number within 24 hrs